Abstracts tagged "interstitial lung disease"

Abstract Number: 1334 • ACR Convergence 2020
Does Interstitial Lung Disease Represent a Real Comorbidity in Spondyloarthritis Patients? Results from an Ultrasound, Monocentric, Pilot Study
Andrea Delle Sedie¹, Emanuele Calabresi¹, Ilaria Romagnoli¹, Linda Carli² and Marta Mosca², ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Background/Purpose: Background: Interstitial lung disease (ILD) is a frequent complication in rheumatoid arthritis (RA) where it represents the most common extra-articular involvement (with a prevalence…
Abstract Number: 0918 • ACR Convergence 2020
Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) with and Without Gastroesophageal Reflux Disease: Further Analyses of the SENSCIS Trial
Kristin Highland¹, Gerard Criner², Petros Sfikakis³, Hilario Nunes⁴, Wendy Stevens⁵, Corinna Miede⁶, Margarida Alves⁷ and Michael Kreuter⁸, ¹Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ²Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ³National Kapodistrian University of Athens Medical School, Athens, Greece, ⁴Department of Pulmonology, Hôpital Avicenne, APHP, Bobigny, France, Bobigny, France, ⁵Department of Rheumatology, St Vincent's Hospital, Melbourne, Victoria, Australia, Fitzroy, Victoria, Australia, ⁶mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany, Heidelberg, Germany
Background/Purpose: Gastroesophageal reflux disease (GERD) is a common comorbidity in patients with SSc-ILD and may be associated with progression of SSc-ILD. In the SENSCIS trial…
Abstract Number: 1073 • ACR Convergence 2020
Anti Melanoma Differentiation-associated Protein Gene 5 Antibody Titer Monitoring Is a Useful Indicator for Early Detection of Recurrence in Rapidly Progressive Interstitial Lung Disease Associated with Dermatomyositis
Yuji Hosono¹, Azusa Kojima², Keigo Shimura², Akira Ishii², Yuto Izumi², Kazuki Hirano², Sho Sasaki², Takayoshi Kurabayashi², Noriko Sasaki², Chiho Yamada² and Shinji Sato², ¹Tokai University School of Medicine, Kanagawa, Japan, ²Tokai University School of Medicine, Isehara, Kanagawa, Japan
Background/Purpose: Anti melanoma differentiation-associated gene 5 (MDA5) antibody (Ab) positive dermatomyositis (DM) often complicates rapidly progressive interstitial lung disease (RP-ILD), which shows fatal prognosis at…
Abstract Number: 1382 • ACR Convergence 2020
Changes in Imaging Markers in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib: Sub-Study of the SENSCIS Trial
Stephen Humphries¹, Eric Hachulla², Mark Hamblin³, Takashi Ogura⁴, Dag Wormanns⁵, Carina Ittrich⁶, Frank Risse⁶, Margarida Alves⁷, Martina Gahlemann⁸ and David Lynch⁹, ¹National Jewish Health, Denver, Colorado, USA, Denver, CO, ²Department of Internal Medicine and Clinical Immunology, Université de Lille, Lille, France, Lille, France, ³University of Kansas Hospital, Kansas City, Kansas, USA, Kansas City, KS, ⁴Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Centre, Yokohama, Japan, Yokohama, Japan, ⁵Evangelische Lungenklinik, Berlin, Germany, Berlin, Germany, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, Biberach an der Riss, Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁹National Jewish Health, Denver, Colorado, USA, Denver
Background/Purpose: In the SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) (mL/year) over 52 weeks by…
Abstract Number: 0927 • ACR Convergence 2020
Care Gap in Patients with Systemic Sclerosis with CXR Findings Suggestive of Fibrosis
Sandeep Dhillon¹, Jessica Kapralik², Curtis Sobchak³, Nader Khalidi⁴, Martin Kolb⁵, Nathan Hambly², Gerard Cox², Karen Beattie⁴ and Maggie Larche⁴, ¹McMaster University, Burlington, ON, Canada, ²McMaster University, Hamilton, ³McMaster University, St. Catharines, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵McMaster University and Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamliton, ON, Canada
Background/Purpose: Lung involvement, including interstitial lung disease (ILD), is the leading cause of death in patients with systemic sclerosis (SSc). High resolution CT (HRCT) is…
Abstract Number: 1078 • ACR Convergence 2020
Highly Reactive anti-Jo1 Autoantibodies to Distinct HisRS Variants and Domains Associate with Lung and Joint Involvement in Patients with Myositis
Antonella Notarnicola¹, Charlotta Preger², Susanna L. Lundström², Nuria Renard², Edvard Wigren², Eveline Van Gompel², Angeles S. Galindo-Feria², Helena Persson³, Maryam Fathi⁴, Johan Grunewald², Per-Johan Jakobsson², Susanne Gräslund², Ingrid Lundberg⁵ and Cátia Fernandes-Cerqueira², ¹Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ²Karolinska Institutet, stockholm, Sweden, ³Science for Life Laboratories, KTH, Stockholm, Sweden, ⁴Karolinska University Hospital, stockholm, Sweden, ⁵Division of Rheumatology, Department of Medicine, Karolinska Institutet,, Stockholm, Sweden
Background/Purpose: To address the reactivity and affinity against histidyl-transfer RNA synthetase (HisRS) autoantigen of anti-Jo1 autoantibodies from serum and bronchoalveolar lavage fluid (BALF) and associations…
Abstract Number: 1383 • ACR Convergence 2020
Tocilizumab Shows Potential in Preserving Lung Function in Systemic Sclerosis with Positive anti-topoisomerase-1 (Scl-70): A Single Centre Cohort Study
Yasir Suleman¹, Kristina Clark², Svetlana Nihtyanova³, Voon Ong⁴ and Christopher Denton², ¹Royal Free Hospital London NHS Trust, London, United Kingdom, ²University College London, London, United Kingdom, ³Centre for Rheumatology, Royal Free Campus, UCL Division of Medicine, UK, London, United Kingdom, ⁴UCL, London, United Kingdom
Background/Purpose: Recent Phase II (faSScinate) and Phase III (focuSSced) clinical trials of tocilizumab versus placebo in early dcSSc highlighted the potential impact of tocilizumab on…
Abstract Number: 0929 • ACR Convergence 2020
The Effect of Mycophenolate Mofetil on Pulmonary Function Tests in Patients with Systemic Sclerosis-associated Interstitial Lung Disease, and the Difference Between the African Americans versus Non-African Americans
Afroditi Boulougoura¹, Shannon Lance², Duncan Moore³, Haijun Wang⁴, Julio Huapaya⁵ and Virginia Steen³, ¹Department of Internal Medicine, Medstar Georgetown University Hospital, Washington, DC, USA., Washington, DC, ²Department of Internal Medicine, Medstar Georgetown University Hospital, Washington, DC, USA., Washington, ³Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ⁴MedStar Health Research Institute, Washington, DC, USA, Washington, ⁵Department of Critical Care Medicine, National Institutes of Health, Bethesda, MD, USA., Bethesda
Background/Purpose: Scleroderma-related interstitial lung disease (SSc-ILD) is a pulmonary fibrosing disorder characterized by systemic inflammation and progressive scarring of the lungs that leads to respiratory…
Abstract Number: 1082 • ACR Convergence 2020
The Presence of Anti-Jo1, anti-PL7, And/or anti-MDA5 Antibodies in Idiopathic Inflammatory Myopathy Confers an Increased Risk of a Significant Restrictive Pulmonary Defect
Dmitriy Cherny¹ and Carrie Richardson¹, ¹Rush University Medical Center, Chicago, IL
Background/Purpose: A subset of patients with idiopathic inflammatory myopathy develop significant restrictive lung disease, although risk factors for this are poorly defined. Autoantibodies may be…
Abstract Number: 1431 • ACR Convergence 2020
Interstitial Lung Disease in Patients with ANCA Associated Vasculitis – a Prospective Single Centre Study
Alojzija Hocevar¹, Katja Perdan Pirkmajer¹, Matija Tomsic¹ and Ziga Rotar¹, ¹University Medical Center Ljubljana, LJUBLJANA, Slovenia
Background/Purpose: Recently, an association between anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and interstitial lung disease (ILD) has been uncovered. We aimed to determine the rate…
Abstract Number: 0995 • ACR Convergence 2020
Jo-1-Binding B Cells Undergo Limited Class-Switching but Are Biased Towards Autoreactive-Prone and Memory B Cell Subsets in Anti-histidyl-tRNA Synthetase Syndrome
Jennifer Young-Glazer¹, Alberto Cisneros², Erin Wilfong¹, Scott Smith¹, Leslie J. Crofford¹ and Rachel Bonami¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbit University Medical Center, Nashville, TN
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are systemic autoimmune diseases traditionally classified as dermatomyositis or polymyositis, but these disorders are increasingly defined by the presence of…
Abstract Number: 1091 • ACR Convergence 2020
A Computer-Aided Diagnostic System for Quantitative Scoring of Extent of Interstitial Lung Disease (ILD) in Dermatomyositis/Polymyositis Associated ILD
Sangmee Bae¹, Andrea Oh², Grace Kim³, Jonathan Goldin³ and Christina Charles-Schoeman⁴, ¹University of California Los Angeles, Los Angeles, CA, ²National Jewish Health, Denver, CO, ³University of California, Los Angeles, Los Angeles, ⁴University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Interstitial lung disease (ILD) occurs in up to 80% of patients with dermatomyositis (DM) and polymyositis (PM), and is a leading cause of morbidity…
Abstract Number: 1446 • ACR Convergence 2020
Pregnancy Outcomes in Patients with Interstitial Lung Disease
Aardra Rajendran¹, Stephanie Giattino², Amanda Eudy³, Aparna Swaminathan⁴ and Megan Clowse⁵, ¹Duke University, Lewisville, NC, ²Duke University, Media, PA, ³Duke University, Durham, NC, ⁴Duke University, Durham, ⁵Duke University, Chapel Hill, NC
Background/Purpose: Patients with interstitial lung disease (ILD) are often recommended to avoid conception or terminate pregnancy despite limited data on pregnancy outcomes and complications. Studies…
Abstract Number: 1046 • ACR Convergence 2020
Risk Factors Associated with Interstitial Lung Disease in Patients with RA: Findings from a Retrospective Healthcare Database Analysis
Joe Zhuo¹, Qisu Zhang², Keith Knapp³, Yuexi Wang⁴, Cynthia Gutierrez⁴, Ding He⁴, Lin Xie⁴, Sonie Lama¹ and Gary Craig⁵, ¹Bristol-Myers Squibb Company, Princeton, NJ, ²STATinMED Research (at time of analysis), Ann Arbor, MI, ³Discus Analytics LLC, Spokane, WA, ⁴STATinMED Research, Ann Arbor, MI, ⁵Arthritis Northwest, PLLC, Spokane, WA
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of RA and is associated with increased morbidity and mortality.1 Previous studies have shown variability in…
Abstract Number: 1096 • ACR Convergence 2020
Assessing Interstitial Lung Disease in a Racially Diverse Population with Idiopathic Inflammatory Myositis
Jammie Law¹, Ana Valle², Katherine Mullins³ and Shereen Mahmood⁴, ¹Montefiore Medical Center, Bronx, NY, ²Albert Einstein College of Medicine, New York, NY, ³Montefiore Medical Center, BROOKLYN, NY, ⁴Albert Einstein College of Medicine / Montefiore Medical Center, Wantagh, NY
Background/Purpose: Interstitial lung disease (ILD) is a common extra-muscular manifestation of Idiopathic Inflammatory Myositis (IIM) and increases risk of mortality. Prior studies and registries have focused on either smaller cohorts or predominantly Caucasian/European populations. Our aim was to better characterize the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].